CTOs on the Move

Inceptor Bio

www.inceptor.bio

 
Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Inceptor Bio raised $37.7M on 03/04/2022

Similar Companies

gloStream

gloStream is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunocore

Immunocore is a privately owned British clinical-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.

Yumanity

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer`s disease, Parkinson`s disease and amyotrophic lateral sclerosis (ALS). The company`s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company`s proprietary platforms have already identified one potential new target for treating Parkinson`s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer`s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.

Bio-Solutions Corporation

Bio-Solutions Corp, Owns and Markets Type2 Defense(TM), a glucose control dietary supplement powder formulated to support healthy glucose levels in addition to maintaining healthy blood pressure.   The company believes that there is a growing Diabetic target market place that lacks adequate healthy tools to maintain healthy blood glucose levels. Type2 Defense is a powder blend of natural ingredients that has been developed to maintain healthy blood glucose levels.

EYELA Tokyo Rikakikai Co

EYELA Tokyo Rikakikai Co is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.